150 related articles for article (PubMed ID: 11306447)
41. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
42. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.
Seidl C; Schröck H; Seidenschwang S; Beck R; Schmid E; Abend M; Becker KF; Apostolidis C; Nikula TK; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):274-85. PubMed ID: 15791436
[TBL] [Abstract][Full Text] [Related]
43. Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy.
Fani M; Xanthopoulos S; Archimandritis SC; Stratis N; Bouziotis P; Loudos G; Varvarigou AD
Anticancer Res; 2003; 23(3A):2195-9. PubMed ID: 12894597
[TBL] [Abstract][Full Text] [Related]
44. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
45. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
46. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
47. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody.
De Santis R; Albertoni C; Petronzelli F; Campo S; D'Alessio V; Rosi A; Anastasi AM; Lindstedt R; Caroni N; Arseni B; Chiodi P; Verdoliva A; Cassani G; Chinol M; Paganelli G; Carminati P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2191-6. PubMed ID: 16609034
[TBL] [Abstract][Full Text] [Related]
48. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
49. E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells.
Suriano G; Oliveira MJ; Huntsman D; Mateus AR; Ferreira P; Casares F; Oliveira C; Carneiro F; Machado JC; Mareel M; Seruca R
Hum Mol Genet; 2003 Nov; 12(22):3007-16. PubMed ID: 14500541
[TBL] [Abstract][Full Text] [Related]
50. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
[TBL] [Abstract][Full Text] [Related]
51. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA
Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248
[TBL] [Abstract][Full Text] [Related]
52. Enhanced cell-substratum adhesion of E-cadherin-expressing cells is mediated by activation of the small GTPase protein, Rac1.
Wang Y; Ohkubo T; Tsubouchi H; Ozawa M
Int J Mol Med; 2006 Apr; 17(4):637-42. PubMed ID: 16525721
[TBL] [Abstract][Full Text] [Related]
53. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
[TBL] [Abstract][Full Text] [Related]
55. Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2.
Li S; Zhang XY; Qiao TD; Chen XT; Zhang SY; Chen LJ
Oncol Res; 1992; 4(11-12):447-53. PubMed ID: 1299375
[TBL] [Abstract][Full Text] [Related]
56. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells.
Kennel SJ; Stabin M; Roeske JC; Foote LJ; Lankford PK; Terzaghi-Howe M; Patterson H; Barkenbus J; Popp DM; Boll R; Mirzadeh S
Radiat Res; 1999 Mar; 151(3):244-56. PubMed ID: 10073661
[TBL] [Abstract][Full Text] [Related]
57. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
58. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
59. Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences.
Handschuh G; Luber B; Hutzler P; Höfler H; Becker KF
J Mol Biol; 2001 Nov; 314(3):445-54. PubMed ID: 11846558
[TBL] [Abstract][Full Text] [Related]
60. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma.
Alpaugh ML; Tomlinson JS; Kasraeian S; Barsky SH
Oncogene; 2002 May; 21(22):3631-43. PubMed ID: 12032865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
